Linvoseltamab

利诺泽单抗

Report date: 2026/05/15 20:01:45

Base Information

Drug NameLinvoseltamab
Drug Alias Namelinvoseltamab-gcptLynozyficREGN-5458
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 bindersAnti-BCMACytotoxic T lymphocytes stimulants +[4] 
TargetsT cell surface glycoprotein CD3B-cell maturation protein
Therapy Area/IndicationsFood HypersensitivityMonoclonal Gammopathy of Undetermined SignificanceRenal Insufficiency, Chronic +[6] 
Global Approved IndicationsMultiple Myeloma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2025/04/23
Country/TerritoryBelgiumCanadaUnited States +[21] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesRegeneron Ireland Designated Activity CompanySanofiRegeneron Pharmaceuticals Inc
Inactive CompaniesMultiple Myeloma Research Consortium Llc
Active IndicationsFood HypersensitivityMonoclonal Gammopathy of Undetermined SignificanceRenal Insufficiency, Chronic +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG